Inactive Instrument

Highlights Ra Pharmaceuticals, Inc.

Equities

US74933V1089

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

UCB SA completed the acquisition of Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.	20-04-01	CI
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-27	CI
Ra Pharmaceuticals, Inc. Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	20-02-18	CI
Ra Pharmaceuticals, Inc. Announces Clearance of IND Application for the HEALEY ALS Platform Trial	20-01-22	CI
Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	19-12-04	CI
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
UCB SA entered into an agreement to acquire Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and Ra Capital Management, LLC and others for $2.3 billion.	19-10-09	CI
Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for GMG	19-10-02	CI
Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck	19-08-21	CI
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI
Ra Pharmaceuticals, Inc. Approves Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for the Year Ending December 31, 2019	19-06-12	CI
Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy	19-06-04	CI
Ra Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019	19-05-09	CI
Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study	19-04-09	CI
Ra Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018	19-03-07	CI
Ra Pharmaceuticals, Inc. Announces Positive Top-Line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis	18-12-10	CI
Ra Pharmaceuticals, Inc. Receives Development Milestone Payment Under Agreement with Merck	18-12-06	CI
Ra Pharmaceuticals, Inc Announces Financial Results for the Third Quarter Ended September 30, 2018	18-11-07	CI
Ra Pharmaceuticals, Inc. Announces Positive Results from Phase 1B Pharmacokinetic Study of Zilucoplan in Patients with Renal Impairment	18-09-26	CI
Ra Pharmaceuticals, Inc. Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program	18-09-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ra Pharmaceuticals, Inc.

Equities

US74933V1089

Highlights

Filters